BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 16203930)

  • 41. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study.
    Suttorp MJ; Laarman GJ;
    Am Heart J; 2007 Sep; 154(3):432-5. PubMed ID: 17719285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients.
    Gershlick A; Kandzari DE; Leon MB; Wijns W; Meredith IT; Fajadet J; Popma JJ; Fitzgerald PJ; Kuntz RE;
    Am J Cardiol; 2007 Oct; 100(8B):45M-55M. PubMed ID: 17950832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.
    Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Urban P; Gershlick AH; Guagliumi G; Guyon P; Lotan C; Schofer J; Seth A; Sousa JE; Wijns W; Berge C; Deme M; Stoll HP;
    Circulation; 2006 Mar; 113(11):1434-41. PubMed ID: 16534015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of treatment of coronary artery disease with sirolimus-eluting stents on outcomes of diabetic and nondiabetic patients.
    Kuchulakanti PK; Torguson R; Canos D; Rha SW; Chu WW; Clavijo L; Deible R; Gevorkian N; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
    Am J Cardiol; 2005 Oct; 96(8):1100-6. PubMed ID: 16214445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.
    Boyden TF; Nallamothu BK; Moscucci M; Chan PS; Grossman PM; Tsai TT; Chetcuti SJ; Bates ER; Gurm HS
    Am J Cardiol; 2007 May; 99(10):1399-402. PubMed ID: 17493468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.
    Kumbhani DJ; Bavry AA; Kamdar AR; Helton TJ; Bhatt DL
    Am Heart J; 2008 Apr; 155(4):640-7. PubMed ID: 18371470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database.
    Liu HB; Xu B; Yang YJ; Wang Y; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li JJ; Qiao SB; Chen JL; Li W; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):681-6. PubMed ID: 19323934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial.
    Fajadet J; Morice MC; Bode C; Barragan P; Serruys PW; Wijns W; Constantini CR; Guermonprez JL; Eltchaninoff H; Blanchard D; Bartorelli A; Laarman GJ; Perin M; Sousa JE; Schuler G; Molnar F; Guagliumi G; Colombo A; Ban Hayashi E; Wülfert E
    Circulation; 2005 Mar; 111(8):1040-4. PubMed ID: 15723977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early and mid-term results of drug-eluting stent implantation in unprotected left main.
    Chieffo A; Stankovic G; Bonizzoni E; Tsagalou E; Iakovou I; Montorfano M; Airoldi F; Michev I; Sangiorgi MG; Carlino M; Vitrella G; Colombo A
    Circulation; 2005 Feb; 111(6):791-5. PubMed ID: 15699254
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Sirolimus-eluting stents to treat lesions with a high risk of restenosis. Six-month clinical follow-up in the first 100 patients].
    de la Torre Hernández JM; Burgos V; González-Enríquez S; Cobo M; Zueco J; Figueroa A; Colman T
    Rev Esp Cardiol; 2004 Feb; 57(2):116-22. PubMed ID: 14967106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    Circulation; 2004 Apr; 109(16):1942-7. PubMed ID: 15078803
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Buellesfeld L; Grube E
    Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.